Wednesday, March 17, 2010 Last update: 2:30 PM

State-by-State AND City-by-City FreshNews.com Delivers Company Tech News

Salix Pharmaceuticals, Ltd.

print this company - email to a friend - join our eNewsletter

News articles for Salix Pharmaceuticals, Ltd.:

Tuesday, March 9, 2010

Salix Pharmaceuticals Reports 4Q2009 and FY2009 Results

Posted at 03/09/2010 - 4:05pm

Tuesday, February 23, 2010

NASDAQ Halts Trading Today in Salix Pharmaceuticals Stock

Posted at 02/23/2010 - 7:01am

Tuesday, November 24, 2009

Salix Pharmaceuticals to Present at Piper Jaffray Conference

Posted at 11/24/2009 - 7:00am

Monday, November 23, 2009

Salix Pharmaceuticals, Ltd. Completes Sale of 6.325 Million Shares of Common Stock

Posted at 11/23/2009 - 11:50am

Wednesday, November 18, 2009

Salix Pharmaceuticals, Ltd. Announces Pricing of a Public Offering of Common Stock

Posted at 11/18/2009 - 9:09am

Tuesday, November 3, 2009

Salix Pharmaceuticals Secures Additional Intellecutual Property Relating to Rifaximin

Posted at 11/03/2009 - 9:09am

Monday, November 2, 2009

Salix Pharmaceuticals Reviews American Association for the Study of Liver Diseases Annual Meeting

Posted at 11/02/2009 - 6:00am

Monday, October 26, 2009

Salix Pharmaceuticals Announces 3Q2009 Financial Results Conference Call and Webcast

Posted at 10/26/2009 - 4:00am

Monday, October 5, 2009

Salix Pharmaceuticals Acquires U.S. Right to Lupin’s Proprietary Bioadhesive Technology for Extended Release Rifaximin Product

Posted at 10/05/2009 - 4:00am

Monday, September 28, 2009

Salix Pharmaceuticals to Present at JMP Securities Conference

Posted at 09/28/2009 - 8:15am

Tuesday, September 8, 2009

Salix Receives FDA Marketing Approval for METOZOLV™ ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD

Posted at 09/08/2009 - 7:00am

Wednesday, September 2, 2009

Salix Pharmaceuticals to Present at Thomas Weisel Partners Conference

Posted at 09/02/2009 - 4:00am

Monday, August 24, 2009

Salix Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review Designation For Rifaximin NDA For the Maintenance of Remission of Hepatic Encephalopathy

Posted at 08/24/2009 - 12:36pm

Wednesday, July 29, 2009

Salix Pharmaceuticals to Present at BMO Conference

Posted at 07/29/2009 - 4:00am

Monday, July 27, 2009

Salix Pharmaceuticals Announces 2Q2009 Financial Results Conference Call and Webcast

Posted at 07/27/2009 - 4:00am

Monday, June 1, 2009

Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW)

Posted at 06/01/2009 - 4:00am

Monday, May 11, 2009

Certain Salix Officers and Directors Adopt 10b5-1 Trading Plans for Stock Options that are Scheduled to Expire During 2010

Posted at 05/11/2009 - 5:30am

Tuesday, May 5, 2009

Salix Pharmaceuticals Reports 1Q2009 Results

Posted at 05/05/2009 - 1:01pm
Salix Pharmaceuticals to Present at Bank of America and Merrill Lynch Conference

Posted at 05/05/2009 - 4:00am

Thursday, April 23, 2009

Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)

Posted at 04/23/2009 - 4:00am

Add new comment

Biotech/Biomedical/Health

Science/ Research

Trade Shows

Financials/Webcasts

Massachusetts

North Carolina

United States